Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Potassium Ion SCHEMBL952692 | 0.93 | TSHR (0.33) | TSHR | |
| SCHEMBL1800340 | 0.93 | TSHR (0.33) | TSHR | |
| Lithium Ion SCHEMBL22445007 | 0.93 | TSHR (0.33) | TSHR | |
| SCHEMBL332719 | 0.93 | TSHR (0.38) | TSHR | |
| SCHEMBL312679 | 0.89 | TSHR (0.35) | TSHR | |
| SCHEMBL43618 | 0.89 | TSHR (0.35) | TSHR | |
| SCHEMBL10535072 | 0.89 | TSHR (0.35) | TSHR | |
| Ammonia Solution, Strong SCHEMBL19874799 | 0.89 | TSHR (0.35) | TSHR | |
| SCHEMBL476435 | 0.89 | TSHR (0.35) | TSHR | |
| SCHEMBL6563690 | 0.89 | TSHR (0.35) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3466934-B1 | SULFONAMIDE COMPOUNDS OR SALT THEREOF AS RIBONUCLEOTIDE REDUCTASE INHIBITORS FOR TREATING CANCER | TAIHO PHARMACEUTICAL CO LTD (JP) | 2024-03-27 | — | — | EP | disclosed |
| US-11634395-B2 | Sulfonamide compound or salt thereof | Taiho Pharmaceutial Co., Ltd. (JP) | 2023-04-25 | — | — | US | disclosed |
| US-20220363667-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | NIPPON CHEMIPHAR CO., LTD. (JP) | 2022-11-17 | — | — | US | disclosed |
| EP-3825303-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | Nippon Chemiphar Co., Ltd. (JP) | 2021-05-26 | — | — | EP | disclosed |
| US-20210101862-A1 | DIAMINE COMPOUND, METHOD OF PREPARING DIAMINE COMPOUND, AND POLYIMIDE | ARAKAWA CHEMICAL INDUSTRIES, LTD. (JP) | 2021-04-08 | — | — | US | disclosed |
| WO-2021029395-A1 | COMPOUND, POLYMER, COMPOSITION, COMPOSITION FOR FILM FORMATION, PATTERN FORMING METHOD, METHOD FOR FORMING INSULATING FILM, METHOD FOR PRODUCING COMPOUND, IODINE-CONTAINING VINYL POLYMER AND METHOD FOR PRODUCING ACETYLATED DERIVATIVE OF SAME | 三菱瓦斯化学株式会社 | 2021-02-18 | — | — | WO | disclosed |
| US-10889555-B2 | Sulfonamide compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-01-12 | — | — | US | disclosed |
| US-20200405697-A1 | Antitumor Agent | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-12-31 | — | — | US | disclosed |
| US-20200399235-A1 | Sulfonamide Compound or Salt Thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-12-24 | — | — | US | disclosed |
| EP-3718545-A1 | ANTITUMOR AGENT | Taiho Pharmaceutical Co., Ltd. (JP) | 2020-10-07 | — | — | EP | disclosed |
| EP-0610192-A1 | ETHER DERIVATIVES OF ALKYL PIPERIDINES AND PYRROLIDINES AS ANTIPSYCHOTIC AGENTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-08-17 | — | — | EP | disclosed |
| US-5317024-A | Administering to mammals | DUPONT MERCK PHARMACEUTICAL CO. (US) | 1994-05-31 | — | — | US | disclosed |
| US-5252586-A | Ether derivatives of alkyl piperidines and pyrrolidines as antipsychotic agents | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-10-12 | — | — | US | disclosed |
| WO-1993009094-A1 | ETHER DERIVATIVES OF ALKYL PIPERIDINES AND PYRROLIDINES AS ANTIPSYCHOTIC AGENTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-05-13 | — | — | WO | disclosed |
| WO-1990005730-A2 | NOVEL CYCLOBUTANE DERIVATIVE AND PROCESS FOR PRODUCING SAME | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1990-05-31 | — | — | WO | disclosed |
| EP-0358154-A2 | Novel cyclobutane derivative and process for producing same | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1990-03-14 | — | — | EP | disclosed |
| US-4906663-A | 6-fluoroprostaglandins | ASAHI GLASS COMPANY, LTD. (JP) | 1990-03-06 | — | — | US | disclosed |
| EP-0312055-A2 | 6-Fluoroprostaglandins | ASAHI GLASS COMPANY LTD. (JP) | 1989-04-19 | — | — | EP | disclosed |
| US-4578482-A | Process for preparing prostacyclins | TEIJIN LIMITED (JP) | 1986-03-25 | — | — | US | disclosed |
| EP-0113577-A1 | Process for preparing prostacyclins | TEIJIN LIMITED (JP) | 1984-07-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399235-A1 | Sulfonamide Compound or Salt Thereof | RNASEH1, SNRPA1, RRM2 | TSHR 840/4885 |
| US-20210101862-A1 | DIAMINE COMPOUND, METHOD OF PREPARING DIAMINE COMPOUND, AND POLYIMIDE | PARP2, RFC2, PARP12 | TSHR 2270/4885 |
| US-10889555-B2 | Sulfonamide compound or salt thereof | RNASEH1, SNRPA1, RRM2 | TSHR 840/4885 |
| US-20220363667-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | CACNA1I, CACNA1G, CACNA1H | TSHR 604/4885 |
| US-11634395-B2 | Sulfonamide compound or salt thereof | RNASEH1, SNRPA1, RRM2 | TSHR 840/4885 |
| US-20200405697-A1 | Antitumor Agent | HNRNPR, RRM2, RRM2B | TSHR 284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.